BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/25/2021 10:52:18 AM | Browse: 872 | Download: 2692
Publication Name World Journal of Clinical Cases
Manuscript ID 59680
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Case Report
Article Title Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
Manuscript Source Unsolicited Manuscript
All Author List Yu Zhang, Di Wu, Bo Zhao, Xue-Liang Tian, Tian-Cheng Yao, Feng Li, Wei-Fang Liu and Ai-Ping Shi
ORCID
Author(s) ORCID Number
Yu Zhang http://orcid.org/0000-0001-6242-3146
Di Wu http://orcid.org/0000-0001-5005-8540
Bo Zhao http://orcid.org/0000-0002-8668-0435
Xue-Liang Tian http://orcid.org/0000-0002-4071-3449
Tian-Cheng Yao http://orcid.org/0000-0002-6177-2739
Feng Li http://orcid.org/0000-0002-5029-6247
Wei-Fang Liu http://orcid.org/0000-0002-3507-382X
Ai-Ping Shi http://orcid.org/0000-0002-7272-453X
Funding Agency and Grant Number
Funding Agency Grant Number
Health Specific Program of Jilin Province, China 2018SCZWSZX-035
Scientific and Technological Development Program of Jilin Province, China 20190701041GH
Corresponding Author Ai-Ping Shi, MD, PhD, Professor, Department of Breast Surgery, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. sap@jlu.edu.cn
Key Words Occult breast cancer; Neoadjuvant chemotherapy; Anlotinib; Mastectomy; Pathological complete response; Case report
Core Tip Occult breast cancer (OBC) is a rare type of breast cancer and there are some difficulties and confusion in its diagnosis and treatment. Biopsy and immunohistochemical analysis can help to make a diagnosis after excluding the possibility of other primary cancers. Because of its low incidence, there is no systematic and standard treatment plan. We first reported the application of neoadjuvant chemotherapy combined with anlotinib in OBC, and pathologic complete response was obtained after operation. This case may provide a new, suitable treatment option for these patients.
Publish Date 2021-01-25 10:52
Citation Zhang Y, Wu D, Zhao B, Tian XL, Yao TC, Li F, Liu WF, Shi AP. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature. World J Clin Cases 2021; 9(4): 919-926
URL https://www.wjgnet.com/2307-8960/full/v9/i4/919.htm
DOI https://dx.doi.org/10.12998/wjcc.v9.i4.919
Full Article (PDF) WJCC-9-919.pdf
Full Article (Word) WJCC-9-919.docx